Formailide derivatives as beta2-adrenoreceptor agonists

Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S603000

Reexamination Certificate

active

07045658

ABSTRACT:
The present invention relates to novel compounds of formula (I), to a process for their menufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases

REFERENCES:
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4730008 (1988-03-01), Skidmore et al.
patent: 4853381 (1989-08-01), Finch et al.
patent: 4853382 (1989-08-01), Skidmore et al.
patent: 4908386 (1990-03-01), Finch et al.
patent: 4937268 (1990-06-01), Skidmore et al.
patent: 4963564 (1990-10-01), Skidmore et al.
patent: 4990505 (1991-02-01), Skidmore et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 4997986 (1991-03-01), Mitchell et al.
patent: 5066678 (1991-11-01), Finch et al.
patent: 5099068 (1992-03-01), Mitchell et al.
patent: 5109023 (1992-04-01), Mitchell et al.
patent: 5283262 (1994-02-01), Mitchell et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 69715 (1983-01-01), None
patent: 162576 (1985-11-01), None
patent: 220054 (1987-04-01), None
patent: 220878 (1987-05-01), None
patent: 223410 (1987-05-01), None
patent: 286242 (1988-10-01), None
patent: 303465 (1989-02-01), None
patent: 317206 (1989-05-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2140800 (1984-12-01), None
patent: 2159151 (1985-11-01), None
patent: 2162842 (1986-02-01), None
patent: 2169265 (1986-07-01), None
patent: 2178965 (1987-02-01), None
patent: 0416951 (1991-09-01), None
patent: 2242134 (1991-09-01), None
patent: WO 95/01170 (1995-01-01), None
patent: WO 99/16766 (1999-04-01), None
patent: WO 99/47505 (1999-09-01), None
patent: WO 01/13953 (2001-03-01), None
D. Iakovidis, et al., “Synthesis and beta-adrenoceptor agonist properties of (+/−)-1-(3′,4′-dihydroxyphenoxy)-3-(3″,4″-dimethooxyphenyl)ethylamino-2-propanol hydrochloride, (+/−)-RO363.HCl, and the (2S)-(-)-isomer”, Eurpoean Journal of Medicinal Chemistry, vol. 34, no. 6, Jun. 1999, pp. 539-548.
Fuji et al., “Novel phosphodiesterase 4 inhibitor T-440 reverse and prevents human bronchial contraction induced by allergen,”J Pharmacol Exp Ther284 (1):162 (1998).
Landells et al., “Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294 inhibits ex-vivo agonist-induced-cell activation,”Eur Resp J (lannu Cong Eur Resp Soc, Geneva)12(Suppl. 28) abst P2393 (Sep. 1998).
McHale et al., “Expression of human recombinant cAMP phoshodiesterase isozyme IV reverse growth arrest phenotype in phoshodiesterase-deficient yeat,”Mol Pharmacol39:109-113 (119).
Nicholson et al., “Different modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphdiesterase isoenzymes,”Trends Pharmacol Sci12;19-27 (1991).
Torphy et al., “Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis,”Mol. Pharmacol39:376-384 (1991).
U.S. Appl. No. 10/467,733, Filed Feb. 9, 2004, Biggadike et al.
Thornber, “Isosterism and molecular modification in drug design,”Chemical Society Reviews:8(4)563-580 (1979).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Formailide derivatives as beta2-adrenoreceptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formailide derivatives as beta2-adrenoreceptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formailide derivatives as beta2-adrenoreceptor agonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3556460

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.